Printen
Rode wijn (Resveratrol) goed bij COPD, Astma en Artritis*
Resveratrol, een biofavonoíde die bijv. in rode wijn zit
heeft als ontstekingsremmer duidelijke effecten bij COPD, Astma en vermoedelijk
ook Artritis.
De opname in het lichaam van de meeste supplementen met resveratrol is echter minimaal en kan men beter niet nemen. Wellicht veel beter
zou zijn deze supplementen in een sprayvorm te nemen..
Red
Wine Mist? Resveratrol Shows Potential Effects Against COPD, Asthma, Arthritis
Homing
in on mechanisms for the reported effectiveness of resveratrol, which is found
in red wine, researchers at Imperial College London, England, confirmed its
broad anti-inflammatory action, and found potential for applications in chronic
obstructive pulmonary disease (COPD), asthma, and possibly even arthritis.
Clinical preparation and delivery remain issues, though an aerosol version would
have obvious benefits.
Indeed,
lead researcher Louise Donnelly said "Resveratrol exhibited
anti-inflammatory activity in all the systems we examined: laboratory cells
lines as well as 'real' human airway epithelial cells," or HAEC. The
research paper published by Donnelly et al. in the American Journal of
Physiology-Lung Cellular and Molecular Physiology, notes: "Our study is
novel as it examines the anti-inflammatory mechanism(s) of resveratrol in cells
relevant to human disease and explores all of the proposed mechanisms in a
single study."
Most
importantly, resveratrol "inhibited anti-inflammatory mediator release from
human airway epithelial cells." And contrary to earlier conjecture, the
Imperial College researchers showed that "resveratrol did not act as an
estrogen or glucocorticosteroid," each of which have patient acceptance
issues.
Resveratrol
from red wine has long been associated with the so-called "French
Paradox," reflecting the low incidence of heart disease among the French
despite their relatively high-fat diet. It is a polyphenolic compound found in
the skins of such red fruits as grapes and plums, the red skin of peanuts, and
even peanut butter. However, Donnelly noted there's "no evidence that COPD,
asthma (especially in asthmatic smokers) or related diseases have lower
incidence in France or elsewhere in the Mediterranean region."
OTC
versions not useful: aerosol version needed
Moreover,
Donnelly warned that their research group had "looked at the
over-the-counter" versions of resveratrol and found that "it's not
very pure and probably wouldn't be worth taking." The major problem is
bioavailability. The compound dissolves only in certain solvents, including
alcohol, "and is cleared very rapidly in the liver," Donnelly said.
Especially
for such respiratory diseases as COPD and asthma, developing an aerosol version
for inhalation probably would be a better option," Donnelly said, noting
that it would overcome one of the problems with steroids, which is
noncompliance.
The
current research aimed to confirm and quantify the effect of resveratrol and
quercetin, a related plant-derived polyphenolic compound that often mimics its
diverse activities, and to further study the molecular mechanisms involved.
While
resveratrol "exhibited anti-inflammatory activity in all the systems we
examined," the researchers said, "it appeared to be more effective,
although less potent, than glucocorticoids. Resveratrol also inhibited
inflammatory mediator release from human airway epithelial cells (HAEC),
inhibited iNOS and COX-2 (cyclooxygenase) gene transcription, together with IL-8
and GM-CSF expression in HAEC. The inhibition of iNOS (inducible nitric oxide
synthase) expression and activity in primary HAEC is significant, because
steroids are ineffective in this system," the paper states.
IL-8
(interleukin-8) and GM-CSF (granulocyte-macrophage colony-stimulating factor)
are important in the inflammation development, they noted, because IL-8 plays a
major role in the recruitment of inflammatory leukocytes, particularly
neutrophils, and GM-CSF is a cell survivor factor, thus prolonging the resident
time of inflammatory cells. "The differential inhibitory effects of
resveratrol on IL-8 and GM-CSF release (shown in this study) further suggest
that resveratrol is not simply acting as a general inhibitor of inflammatory
mediator release but exhibits some selectivity."
Next
steps: further narrow mechanisms of broad anti-inflammatory
Donnelly
et al. conclude that resveratrol and quercetin "can act as novel
anti-inflammatory agents. Their mechanism of action is not via the estrogen or
glucocorticoid receptor; thus these agents might be beneficial in inflammatory
diseases where glucocorticosteroids have proved to be ineffective, such as COPD,
steroid-resistant asthma, and arthritis. These compounds may provide candidate
molecules for the development of novel anti-inflammatory therapies."
The
current study "excluded a lot" of potential mechanisms of action,
Donnelly said, but we "still don't know what its target receptor is as it
binds like a protein, but acts like an estrogen," which it's not. "The
good thing is that it does stop inflammation" across a broad range of
systems, she added.
Source
and funding: The article, "Anti-inflammatory effects of resveratrol in lung
epithelial cells: molecular mechanisms," appears in the October issue of
American Journal of Physiology-Lung Cellular and Molecular Physiology, published
by the American Physiological Society.
In
addition to Donnelly, other members of the research team, all from the
Department of Thoracic Medicine, National Heart & Lung Institute, Imperial
College London, England, are: Robert Newton, Gina E. Kennedy, Peter S. Fenwick,
Rachel H.F. Leung, Kazuhiro Ito, Richard E.K. Russell and Peter J. Barnes.
Research
was funded by grants from Pharmascience Inc., Pharmacia (part of Pfizer Inc.),
the British Lung Foundation and the National Asthma Campaign (UK). (Nov. 2004)